audreykahl318
/
audrey2007
1
0
Code Issues Packages Projects Wiki

Add An update on testosterone, HDL and cardiovascular risk in men

Audrey Kahl 2026-04-03 00:49:02 +08:00
commit f5a02eaf6c
1 changed files with 11 additions and 0 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

11
An-update-on-testosterone%2C-HDL-and-cardiovascular-risk-in-men.md Normal file

@ -0,0 +1,11 @@
<br>
<br>However, this was a small study and there is a need to verify the findings and better understand the functional implications of the observed changes in HDL constituent proteins . This prevents the deposition of cholesterol in the arterial wall and thereby protects against atherogenesis. Focus has shifted from measuring HDL cholesterol content alone to assessing HDL particle function, which may prove a better predictor of CVD risk.
They must also decide whether to study men with normal testosterone levels or men who have low levels (called hypogonadism), either because of natural factors or because of androgen-deprivation therapy for prostate cancer. The TRAVERSE trial, a large‐scale, randomized, placebo‐controlled study, provided robust evidence that testosterone therapy does not significantly increase the risk of major adverse cardiovascular events. Although these trials are assessing outcomes in men with hypogonadism and prostate cancer, it is also important to study effects in older men who do not have these conditions, as they have an increased likelihood of using testosterone therapies. The [buy testosterone online without prescription](http://47.112.137.193:3000/stanleylovelad) Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) study is an ongoing clinical trial designed to measure the time to major adverse cardiovascular events in hypogonadal men, aged 45 to 80 years, with increased risk or evidence of CVD.36 The study commenced in May 2018 and is expected to be completed in June 2022, with 6000 planned participants randomized to receive topical testosterone or placebo.36 This clinical trial will play an important role in determining the safety of TRT in hypogonadal men. The indication of an association between testosterone therapy and risk for adverse cardiovascular events prompted the US Food and Drug Administration (FDA) to issue a safety warning on testosterone therapy for older men, which was followed by a reduction in [buy testosterone booster](http://smandamlg.com/vibe/@hubertdesatg85?page=about) prescriptions.30 The safety warning cautioned against the use of testosterone therapy for aging-related decline and reinforced the current approval of testosterone products for hypogonadal men only.30 However, it is important to note that the methodology and reliability of the aforementioned studies have since been questioned. Thus, although many studies have found inverse associations between endogenous testosterone levels and cardiovascular risk and mortality, conflicting results and heterogeneous study populations have prevented firm conclusions from being drawn.
Some biological effects of testosterone may result from its aromatization to estradiol and subsequent interaction with the estrogen receptor. Testosterone (T) is the principal male sex hormone, secreted primarily by the testes and transported in the blood by the carrier protein, sex-hormone binding globulin (SHBG). [buy testosterone powder](https://funsilo.date/wiki/User:ToneyYancy) replacement therapy (TRT) has been shown to improve myocardial ischemia in men with CAD, improve exercise capacity in patients with CHF, and improve serum glucose levels, HbA1c, and insulin resistance in men with diabetes and prediabetes. Studies have reported a reduced CV risk with higher endogenous T concentration, improvement of known CV risk factors with T therapy, and reduced mortality in T-deficient men who underwent T replacement therapy versus untreated men. In the randomized, placebo-controlled T4DM trial involving men with dysglycemia, testosterone treatment on a background of lifestyle intervention reduced risk of type 2 diabetes mellitus after 2 years.
That's because a report from the Massachusetts Male Aging Study found that over half the men with symptomatic [testosterone online pharmacy](https://rightmeet.co.ke/@angelesstonema) deficiency improved without any treatment at all. But even if your levels are low, you may benefit from a period of observation and repeat testing before starting treatment. As a rule of thumb, if your total testosterone is above 300 ng/dL, your free testosterone is above 5 ng/dL, or your bioavailable testosterone is above 150 ng/dL, true deficiency is unlikely. But since normal levels vary so widely, how do you know if your results are really low? Experts do not recommend routine testing for testosterone deficiency. According to one survey, only 12% of men with androgen deficiency were receiving treatment. In all, an average, healthy 65-year-old in 2002 had about 15% less testosterone than a similar 65-year-old in 1987.
Similar to the previous reports, TRT resulted in a significant increase in hemoglobin levels.36 However, none of the individual prostate-related adverse events significantly differed between groups, including incident prostate cancer, which showed no difference between the TRT group and placebo.34 In 2016, Boyle et al. reported results of a meta-analysis on prostate cancer in TRT trials. The TRT group had a significantly greater incidence of all prostate-related adverse events, with a pooled odds ratio of 1.78 (95% CI, 1.07–2.95). All four studies included in this meta-analysis evaluated the effects of TRT on LVEF as well. The authors also verified that the odds ratio for having hypogonadism was significantly higher in obese men, and there was a statistically significant negative correlation between total T level and BMI.15 Testosterone replacement therapy (TRT) has been shown to decrease fat mass. Whether low T and increased mortality are simply covariates or a causal relationship remains to be proven.
TTh aims to restore T levels to the physiological range, thereby alleviating the symptoms of hypogonadism. Male hypogonadism is an endocrine condition of [testosterone purchase](https://gitea.pnkx.top:8/adalbertobetti) deficiency with the potential to cause multiple morbidities and psychosocial complaints. [buy testosterone injections](http://61.190.74.90:9900/danielawindsor/49338.155.160.224/wiki/The-SEEDS-Framework-for-Boosting-Testosterone-Naturally) therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. Moreover, there must be further investigation into mechanisms of action of testosterone.
Androsterone and etiocholanolone are then glucuronidated and to a lesser extent sulfated similarly to testosterone. An additional 40% of [buy testosterone without prescription](https://heywhatsgoodnow.com/@lanestringer53) is metabolized in equal proportions into the 17-ketosteroids androsterone and etiocholanolone via the combined actions of 5α- and 5β-reductases, 3α-hydroxysteroid dehydrogenase, and 17β-HSD, in that [order testosterone online](https://gitea.scivigi.com/adrienemoowatt). Approximately 50% of [testosterone online pharmacy](http://1.13.196.248:3000/hwoaleida91189/aleida1987/wiki/Primary-Testicular-Failure-Endotext-NCBI-Bookshelf) is metabolized via conjugation into [buy testosterone supplements](http://35.207.205.18:3000/nellefortin98) glucuronide and [shqkxh.org](http://shqkxh.org:3000/arnetteharms5) to a lesser extent testosterone sulfate by glucuronosyltransferases and sulfotransferases, respectively. It is bound 65% to sex hormone-binding globulin (SHBG) and 33% bound weakly to albumin. The plasma protein binding of testosterone is 98.0 to 98.5%, with 1.5 to 2.0% free or unbound. The amount of testosterone synthesized is regulated by the hypothalamic–pituitary–testicular axis (Figure 2). In addition, the amount of testosterone produced by existing Leydig cells is under the control of LH, which regulates the expression of 17β-hydroxysteroid dehydrogenase.
Interestingly, these authors reported that when T concentrations were tracked over time, a greater decline was evident among men with multiple CVD risk factors than men without risk factors, with T levels in some subjects reaching the hypogonadal range. However, in an analysis in older men from the Framingham heart study , no association between plasma lipids and T concentrations was observed. These findings prompted a prospective look at the relationship between plasma T levels and dyslipidemia through longitudinal studies.
TRAVERSE's findings are likely to influence future clinical guidelines by supporting a balanced approach to TTh, where its benefits for men with symptomatic hypogonadism—such as reduced fatigue, improved libido, and muscle strength—can be considered with greater confidence. This result supports previous findings that, with appropriate administration, TTh does not elevate CV risk. It builds on previous research by providing a large‐scale, randomized, long‐term analysis that offers a more nuanced understanding of TTh's risks and benefits.
<br>